[Skip to Content]
[Skip to Content Landing]
Views 2,343
Citations 0
Invited Commentary
July 15, 2020

Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?

Author Affiliations
  • 1Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles
JAMA Surg. 2020;155(9):840. doi:10.1001/jamasurg.2020.2302

During the last decade, moderate progress in the treatment of pancreatic ductal adenocarcinoma (PDAC) has been realized with updated chemotherapeutic regimens, advanced operative techniques, and in some cases, targeted genetic-based therapy. Treating patients with borderline resectable or locally advanced tumors using neoadjuvant chemotherapy may provide benefit.1 Current treatment regimens have extrapolated from the success of FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel (GA) in the setting of metastatic PDAC.2,3

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words